MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

Philip A. Beer, Peter J. Campbell, Linda M. Scott, Anthony J. Bench, Wendy N. Erber, David Bareford, Bridget S Wilkins, John T. Reilly, Hans C. Hasselbalch, Richard Bowman, Keith Wheatley, Georgina Buck, Claire N. Harrison, Anthony R. Green

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Activating mutations of MPL exon 10 have been described in a minority of patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and clinical significance are unclear. Here we demonstrate that MPL mutations outside exon 10 are uncommon in platelet cDNA and identify 4 different exon 10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF. Allele-specific polymerase chain reaction was then used to genotype 776 samples from patients with ET entered into the PT-1 studies. MPL mutations were identified in 8.5% of JAK2 V617F(-) patients and a single V617F(+) patient. Patients carrying the W515K allele had a significantly higher allele burden than did those with the W515L allele, suggesting a functional difference between the 2 variants. Compared with V617F(+) ET patients, those with MPL mutations displayed lower hemoglobin and higher platelet levels at diagnosis, higher serum erythropoietin levels, endogenous megakaryocytic but not erythroid colony growth, and reduced bone marrow erythroid and overall cellularity. Compared with V617F(-) patients, those with MPL mutations were older with reduced bone marrow cellularity but could not be identified as a discrete clinicopathologic subgroup. MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation or survival.
Original languageEnglish
JournalBlood
Volume112
Issue number1
Pages (from-to)141-149
Number of pages8
ISSN0006-4971
DOIs
Publication statusPublished - 1. Jul 2008

Fingerprint Dive into the research topics of 'MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort'. Together they form a unique fingerprint.

Cite this